Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: bivatuzumab mertansine

First Posted Date: 2014-10-01

Last Posted Date: 2023-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02254031

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: midazolam
Drug: caffeine
Drug: digoxin
Drug: warfarin
Drug: omeprazole
Drug: BI 187004
Drug: metoprolol

First Posted Date: 2014-10-01

Last Posted Date: 2014-12-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02254148

Locations: 🇩🇪
1307.19.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Atazanavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21

Registration Number: NCT02253836

Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 - D1
Drug: BILR 355 - D2
Drug: BILR 355 - D3
Drug: BILR 355 - D4
Drug: Ritonavir
Other: high fat breakfast

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02253927

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BEA 2180 BR - rising dose
Drug: Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02254109

Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS, D8
Drug: BILR 355 BS, D5
Drug: BILR 355 BS, D7
Drug: BILR 355 BS, D1
Drug: BILR 355 BS, D3
Drug: BILR 355 BS, D4
Drug: BILR 355 BS, D6
Drug: BILR 355 BS, D2
Drug: Placebo
Drug: BILR 355 BS, D10
Drug: Ritonavir
Other: high-fat breakfast

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT02253953

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-Tipranavir
Drug: Tipranavir
Drug: Ritonavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02253797

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Salmeterol capsule - low
Drug: Salmeterol via Serevent® Diskus®
Drug: Salmeterol capsule - high

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02254187

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: bivatuzumab mertansine

First Posted Date: 2014-10-01

Last Posted Date: 2023-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT02254018

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: bivatuzumab mertansine

First Posted Date: 2014-10-01

Last Posted Date: 2023-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02254005

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy